19 February 2019, The global Breast
Cancer Market is
anticipated to witness a significant growth over the forecast period on account
of growing target population base across the globe, rising prevalence of the
disease, unhealthy lifestyle, exposure to radiations, and lack of physical
exercises. Moreover, increasing efforts taken by major organizations across
various regions to increase awareness levels is estimated to drive the market.
Rising investments in R&D by various government and private organizations
for development of effective drugs and treatments is also projected to play a
key role in the market growth.
For instance, CytoDyn Inc., a biotech firm developing
humanized CCR5 monoclonal antibodies for several therapeutic indications,
received FDA approval for its Investigation New Drug (IND) submission and is
allowed to start a phase 1b/2 trial for metastatic Triple-Negative Breast
Cancer (TNBC). This disease subtype is one of the leading causes of cancer
deaths across the globe and it accounts for around 10 % of the overall cases.
The firm has identified several trial sites and aims to dose a few patients and
expects to have initial readout during the first quarter of 2019. Changes in
the number of Circulating Tumor Cells (CTCs) will be assessed every 21 days
throughout the trial.
Breast cancer is detected during a screening test or
after the patient notices a lump, which is the most common physical sign.
According to the World Health organization (WHO), every year, about 200,000 new
cases of breast cancer are diagnosed globally and this number is likely to
increase in future. Some of the major types of breast cancer are ductal
carcinoma in situ (DCIS), Invasive Ductal Carcinoma (IDC), and lobular
carcinoma. Invasive ductal carcinoma hold a major share in the market owing to
growing prevalence of IDC, government support, and initiatives undertaken to
increase awareness among patients. Furthermore, unmet clinical needs in
treatment of IDC has compelled manufacturers to conduct rigorous R&D
activities. Chemotherapy, targeted, surgery and radiation, hormone, and biologic
therapies are some of the most popular treatments for the disease.
North America has emerged as the prominent region in the
market on account of changing lifestyle, growing prevalence of the disease, and
presence of leading companies in U.S. Europe is likely to emerge highly
lucrative over the coming years as a result of increased healthcare expenditure
and technological developments. Countries, including Germany, France, and U.K.,
are some of the key revenue-generating economies in Europe.
Asia pacific is also projected to witness a considerable
growth over the next few years owing to rapidly developing healthcare
infrastructure and rising consumer disposable income. Moreover, ongoing
awareness programs about breast cancer and available treatments by governments
in the emerging countries, such as China and India are estimated to foster the
growth.
Companies are adopting several business strategies, such
as novel product development, technological advancements, and M&A in order
to strengthen their foothold in the industry. For example, FDA recently
approved the Investigational New Drug (IND) application for Athenex’s oral form
of Eribulin. It is an anticancer drug promoted by Eisai Company under the brand
name Halaven and can effectively treat metastatic breast cancer and
liposarcoma. The company is allowed to initiate clinical trial program, which
is expected to start in the first half of 2019. Other targeted therapies
introduced to treat breast cancer include Perjeta (pertuzumab) and Kadcyla
(T-DM1), which is a human antibody-drug conjugate. Leading companies operating
in the global breast cancer market include Pfizer, Inc.; Novartis AG; Apthera,
Inc.; BioNumerik Pharmaceuticals, Inc.; Eli Lilly and Company; and Oncothyreon,
Inc.
Browse Related Category Market Reports @ https://www.hexaresearch.com/research-category/pharmaceuticals-industry
About Us:
Hexa Research is a market research and
consulting organization, offering industry reports, custom research and
consulting services to a host of key industries across the globe. We offer
comprehensive business intelligence in the form of industry reports which help
our clients obtain clarity about their business environment and enable them to
undertake strategic growth initiatives.
Contact Us:
Ryan Shaw
Hexa Research
Felton Office Plaza
6265 Highway 9
Felton, California 95018
United States
Phone: +1-800-489-3075
Website: https://www.hexaresearch.com
